Bin Wu

Company: Cytodigm

Job title: Founder & Chief Executive Officer

Seminars:

Case Study: Building Next-Generation LNPs with Gangliosides Instead of PEG to Reinvent Safety & Mitigate Immunogenicity 8:30 am

Cytodigm successfully developed CytofinityTM LNP by replacing the PEG-lipid with a ganglioside in the LNP formulation The Cytofinity LNP can load various nucleic acid cargos and exhibited good colloidal stability, high encapsulation efficiency, and excellent safety profile The Cytofinity LNP possesses all the benefits of traditional LNPs while also offering additional advantages and capabilitiesRead more

day: Conference Day Two